Hashimoto Y - Search Results

1

The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180.

Aiba T, Susa M, Fukumori S, Hashimoto Y. Aiba T, et al. Among authors: hashimoto y. Drug Metab Pharmacokinet. 2005 Aug;20(4):268-74. doi: 10.2133/dmpk.20.268. Drug Metab Pharmacokinet. 2005. PMID: 16141606

2

Evaluation of limited sampling designs to estimate maximal concentration and area under the curve of mizoribine in pediatric patients with renal disease.

Ishida K, Kaneda H, Uemura O, Ushijima K, Ohta K, Goto Y, Satomura K, Shimizu M, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Takaai M, Hashimoto Y. Ishida K, et al. Among authors: hashimoto y. Drug Metab Pharmacokinet. 2011;26(1):71-8. doi: 10.2133/dmpk.dmpk-10-rg-077. Epub 2010 Oct 22. Drug Metab Pharmacokinet. 2011. PMID: 20978362

3

Functional characteristics of a renal H⁺/lipophilic cation antiport system in porcine LLC-PK₁ cells and rats.

Matsui R, Hattori R, Usami Y, Koyama M, Hirayama Y, Matsuba E, Hashimoto Y. Matsui R, et al. Among authors: hashimoto y. Drug Metab Pharmacokinet. 2018 Feb;33(1):96-102. doi: 10.1016/j.dmpk.2017.11.313. Epub 2017 Dec 5. Drug Metab Pharmacokinet. 2018. PMID: 29338932

4

The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction.

Okabe H, Hasunuma M, Hashimoto Y. Okabe H, et al. Among authors: hashimoto y. Pharm Res. 2003 Oct;20(10):1591-4. doi: 10.1023/a:1026131216669. Pharm Res. 2003. PMID: 14620512

5

Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats.

Aiba T, Takehara Y, Okuno M, Hashimoto Y. Aiba T, et al. Among authors: hashimoto y. Pharm Res. 2003 May;20(5):745-8. doi: 10.1023/a:1023429401738. Pharm Res. 2003. PMID: 12751629

6

Variability of bioavailability and intestinal absorption mechanisms of metoprolol.

Fukao M, Ishida K, Horie A, Taguchi M, Nozawa T, Inoue H, Hashimoto Y. Fukao M, et al. Among authors: hashimoto y. Drug Metab Pharmacokinet. 2014;29(2):162-7. doi: 10.2133/dmpk.dmpk-13-rg-057. Epub 2013 Sep 10. Drug Metab Pharmacokinet. 2014. PMID: 24025984

7

Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.

Yamaura S, Fukao M, Ishida K, Taguchi M, Hashimoto Y. Yamaura S, et al. Among authors: hashimoto y. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):53-9. doi: 10.1007/s13318-013-0140-2. Epub 2013 Jun 6. Eur J Drug Metab Pharmacokinet. 2014. PMID: 23739952

8

Variability of bioavailability and intestinal absorption characteristics of bisoprolol.

Ishida K, Horie A, Nishimura M, Taguchi M, Fujii N, Nozawa T, Inoue H, Hashimoto Y. Ishida K, et al. Among authors: hashimoto y. Drug Metab Pharmacokinet. 2013;28(6):491-6. doi: 10.2133/dmpk.dmpk-13-rg-017. Epub 2013 May 28. Drug Metab Pharmacokinet. 2013. PMID: 23719964

9

Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.

Taguchi M, Ichida F, Hirono K, Miyawaki T, Yoshimura N, Nakamura T, Akita C, Nakayama T, Saji T, Kato Y, Horiuchi I, Hashimoto Y. Taguchi M, et al. Among authors: hashimoto y. Drug Metab Pharmacokinet. 2011 Jun;26(3):280-7. doi: 10.2133/dmpk.DMPK-10-RG-113. Epub 2011 Mar 4. Drug Metab Pharmacokinet. 2011. PMID: 21383523

10

Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction.

Horiuchi I, Mori YI, Taguchi M, Ichida F, Miyawaki T, Hashimoto Y. Horiuchi I, et al. Among authors: hashimoto y. Biopharm Drug Dispos. 2009 Sep;30(6):326-33. doi: 10.1002/bdd.671. Biopharm Drug Dispos. 2009. PMID: 19639656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results